SHIM
KNSA icon

Stone House Investment Management’s Kiniksa Pharmaceuticals KNSA Stock Holding History

Stone House Investment Management’s Portfolio KNSA Stock Details KNSA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$12K Buy
188
+65
+53% +$3.37K ﹤0.01% 402
2026
Q1 		$5.92K Buy
123
+82
+200% +$3.63K ﹤0.01% 430
2025
Q4 		$1.69K Buy
41
+19
+86% +$762 ﹤0.01% 575
2025
Q3 		$854 Buy
+22
New +$715 ﹤0.01% 579

Other funds holding KNSA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Rubric Capital Management (New York)
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
SSC
Spruce Street Capital New York $510M AUM

Stone House Investment Management's KNSA Position: Q2 2026 in Review

Stone House Investment Management increased its Kiniksa Pharmaceuticals (KNSA) stake by 53% in Q2 2026, buying an estimated $3.37K and bringing the position to 188 shares worth $12K. The position accounts for ﹤0.01% of the portfolio, ranked #402.

Stone House Investment Management first reported a position in KNSA in Q3 2025 and has held it in 4 quarters since. 266 funds tracked by Wall St. Rank hold KNSA as of Q2 2026.

  • Stone House Investment Management held 188 shares of Kiniksa Pharmaceuticals worth $12K as of Q2 2026.
  • Stone House Investment Management bought 65 Kiniksa Pharmaceuticals shares in Q2 2026, an estimated $3.37K.
  • Kiniksa Pharmaceuticals made up ﹤0.01% of Stone House Investment Management's portfolio in Q2 2026, its #402 holding.
  • Stone House Investment Management first reported a position in Kiniksa Pharmaceuticals in Q3 2025 and has held it in 4 quarters since.
  • 266 funds tracked by Wall St. Rank held Kiniksa Pharmaceuticals as of Q2 2026.

Based on Stone House Investment Management's 13F filing for Q2 2026, filed 5 Aug 2026.